Research location

Ankeny

Iowa, United States

Published trials43
Site observations43
Linked trials published43
Page1 / 1
Advertisement

Research activity in Ankeny

Iowa, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 43 trials and 43 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Ankeny

43 linked trials · page 1 of 1
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · 2026-08-10 · 1 site observation
RECRUITING
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialNCT07200830 · 2026-03-31 · 1 site observation
RECRUITING
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerNCT06686771 · 2025-12-16 · 1 site observation
RECRUITING
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyNCT06769126 · 2025-11-06 · 1 site observation
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation
RECRUITING
E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation
RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28 · 1 site observation
RECRUITING
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635 · 2025-04-01 · 1 site observation
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 1 site observation
RECRUITING
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)NCT06031688 · 2024-08-08 · 1 site observation
RECRUITING
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · 2024-07-19 · 1 site observation
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation
RECRUITING
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05 · 1 site observation
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 1 site observation
RECRUITING
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsNCT04665739 · 2023-02-03 · 1 site observation
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18 · 1 site observation
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 1 site observation
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)NCT05554354 · 2024-09-13 · 1 site observation
TERMINATED
Mobile Health for Adherence in Breast Cancer PatientsNCT06112613 · 2024-04-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE TrialNCT06216574 · 2024-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsNCT05896189 · 2024-02-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With PaclitaxelNCT05751668 · 2023-11-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialNCT05554380 · 2023-09-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast CancerNCT05705401 · 2023-05-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeNCT04929041 · 2022-10-07 · 1 site observation
ACTIVE_NOT_RECRUITING
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close MonitoringNCT04597359 · 2021-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04625647 · 2021-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsNCT04310020 · 2021-01-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialNCT04402788 · 2021-01-07 · 1 site observation
SUSPENDED
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE TrialNCT04134260 · 2020-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerNCT03793179 · 2019-04-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)NCT02194738 · 2014-09-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.